Abstract:More than 10% of nasopharyngeal cancer (NPC) patients develop local recurrence after definitive radiotherapy or chemoradiation. Re-irradiation (re-RT) with X-ray-based intensity-modulated radiotherapy (IMXT) is the most accepted treatment for salvaging locally recurrent NPC (LR-NPC) especially for those at locally advanced stages. However, the reported 2-year overall survival (OS) rates only ranged between 45∼60% for locally advanced LR-NPC after salvage IMXT largely due to treatment-induced toxicities. Due to its inherent physical and biological advantages, carbon-ion radiotherapy (CIRT) is feasible and potentially effective for LR-NPC. Here we report the 1-year outcomes of our phase I/II trial in terms of survival, disease control, and toxicities of LR-NPC patients treated at the maximal tolerable dose (MDT) of CIRT re-RT. This open-label single arm phase I/II trial enrolled pathologically and/or clinically confirmed LR-NPC (age 18∼70 years) diagnosed >12 months after the completion of initial IMXT. In the phase I study, the Time-to-Event Continual Reassessment Method was used to determine, via a dose-escalation scheme, the MTD of CIRT re-RT. The primary end point of the phase II part was patients' 2-year OS. Severe (i.e., Grade 4 or 5) acute and subacute toxicities were analyzed. All patents were treated at 3 Grey Equivalent (GyE) per daily fraction, 5 days a week, using intensity-modulated CIRT with raster-scanning technology. Neoadjuvant chemotherapy (cisplatin + docetaxel or gemcitabine) was recommended for patients with stage III-IVA/B LR-NPC, but concurrent chemotherapy was prohibited. Sixteen patients were accrued to the phase I dose escalating (range 51∼63GyE in 17∼21 fractions) protocol. No patient experienced grade 4 toxicities, thus the MTD was set at 63 GyE/21 fractions, the highest of the protocol dose scheme. Thirty-nine LR-NPC patients (AJCC stage I/II/III/IVA-B disease in 4/8/10/17 patients) were accrued to the phase II study. All patients completed planned 63GyE/21 daily fractions without break. With a median follow-up of 8.4 (range 2.0∼21.9) months, 1 patient died from massive hemorrhage subsequent to mucosal necrosis. The 1-year overall, local progression-free, regional recurrence-free, and distant metastasis free survival rates were 95.0%, 87.1%, 96.4%, and 100%, respectively. No patient experienced acute toxicity of ≥ grade 3. Grade 3 or above late toxicities observed included mucosal necrosis (5.1%), xerostomia (2.6%), hearing loss (5.1%), and temporal lobe necrosis (2.6%). This was the first prospective clinical trial to evaluate the efficacy and safety of CIRT for LR-NPC. Our results suggested that CIRT provided promising OS at 1 year with infrequent severe toxicities.

Is fractionated robotic stereotactic body radiosurgery optional salvage treatment for the re-irradiation of locally recurrent nasopharyngeal carcinoma?

Robotic system-based fractionated stereotactic radiotherapy in locally recurrent nasopharyngeal carcinoma

Outcome of fractionated stereotactic radiotherapy for 90 patients with locally persistent and recurrent nasopharyngeal carcinoma.

Robotic stereotactic body radiotherapy for recurrent nasopharyngeal carcinoma

Re-irradiation with Moderate Hypo-fractionation Using Intensity Modulated Photon or Proton Radiation Therapy in Locally Recurrent Squamous Cell Carcinoma of Nasopharynx

Prognostic factors of locally persistent and recurrent nasopharyngeal carcinoma treated with ster-eotactic radiotherapy

A retrospective comparison of robotic stereotactic body radiotherapy and three-dimensional conformal radiotherapy for the reirradiation of locally recurrent nasopharyngeal carcinoma

Long-term survival and late complications of intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma

Long-term treatment outcome of recurrent nasopharyngeal carcinoma treated with salvage intensity modulated radiotherapy.

Experience in fractionated stereotactic body radiation therapy boost for newly diagnosed nasopharyngeal carcinoma

Phase I/II Trial Evaluating Carbon-Ion Radiotherapy for Salvage Treatment of Locally Recurrent Nasopharyngeal Carcinoma

Intensity-modulated radiation therapy in the salvage of locally recurrent nasopharyngeal carcinoma

Comparison of Stereotactic Radiosurgery and Radiotherapy in Salvaging Local Failures of Nasopharyngeal Carcinoma

Clinical results of proton therapy reirradiation for recurrent nasopharyngeal carcinoma

Long-Term Outcomes and Prognostic Factors of Re-Irradiation for Locally Recurrent Nasopharyngeal Carcinoma Using Intensity-Modulated Radiotherapy

Long-term Survival and Late Complications in Intensity-Modulated Radiotherapy of Locally Recurrent T1 to T2 Nasopharyngeal Carcinoma.

Effectiveness And Toxicities Of Intensity-Modulated Radiotherapy For Patients With Locally Recurrent Nasopharyngeal Carcinoma

Salvage Endoscopic Nasopharyngectomy and Intensity-Modulated Radiotherapy Versus Conventional Radiotherapy in Treating Locally Recurrent Nasopharyngeal Carcinoma.

Impact of Radiotherapy Combined with Chemotherapy on Long-Term Outcomes of Patients with Recurrent Nasopharyngeal Carcinoma

The Challenge in Treating Locally Recurrent T3-4 Nasopharyngeal Carcinoma: the Survival Benefit and Severe Late Toxicities of Re-Irradiation with Intensity-Modulated Radiotherapy.

Long-term efficacy of hyperfractionated intracavitary brachytherapy on 69 patients with locally recurrent nasopharyngeal carcinoma